Tumour initiating cells and IGF/FGF signalling contribute to sorafenib resistance in hepatocellular carcinoma

Gut

Volumn 66, Issue 3, 2017, Pages 530-540

  Tovar, Victoria ^a   Cornella, Helena ^a   Moeini, Agrin ^a   Vidal, Samuel ^b   Hoshida, Yujin ^b   Sia, Daniela ^a,b,c   Peix, Judit ^a   Cabellos, Laia ^a   Alsinet, Clara ^a   Torrecilla, Sara ^a   Martinez Quetglas, Iris ^a   Lozano, Juan José ^d   Desbois Mouthon, Christèle ^e,f   Solé, Manel ^a   Domingo Domenech, Josep ^b   Villanueva, Augusto ^b   Llovet, Josep M ^a,b,g  

^a UNIVERSITY OF BARCELONA   (Spain)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NATIONAL CANCER INSTITUTE   (Italy)

^d INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^e SORBONNE UNIVERSITÉ   (France)

^f CENTRE DE RECHERCHE SAINT ANTOINE   (France)

^g INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

Author keywords

drug resistance; Hepatocellular carcinoma; molecular genetics; molecular mechanisms; stem cells

Indexed keywords

FIBROBLAST GROWTH FACTOR; SOMATOMEDIN; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; FGFR1 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR RECEPTOR 1; IGF1R PROTEIN, HUMAN; NICOTINAMIDE; SOMATOMEDIN RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CELL VIABILITY; CONTROLLED STUDY; DRUG EFFECT; DRUG RESPONSE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PREDICTION; SIGNAL TRANSDUCTION; TUMOR CELL; TUMOR INITIATING CELL; AGED; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; DRUG RESISTANCE; DRUG SCREENING; FEMALE; GENE EXPRESSION PROFILING; GENETICS; LIVER NEOPLASMS; MALE; METABOLISM; MULTICELLULAR SPHEROID; PATHOLOGY; SURVIVAL RATE; TUMOR CELL LINE;

AGED; ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; FEMALE; FIBROBLAST GROWTH FACTORS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED BALB C; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTOR, FIBROBLAST GROWTH FACTOR, TYPE 1; RECEPTORS, SOMATOMEDIN; SIGNAL TRANSDUCTION; SOMATOMEDINS; SPHEROIDS, CELLULAR; SURVIVAL RATE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 85014734014     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2015-309501     Document Type: Article

References (33)

1. Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87-108.
2. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008;359:378-90.
3. Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2002;2:117-25.
4. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011;364:2507-16.
5. Rudalska R, Dauch D, Longerich T, et al. In vivo RNAi screening identifies a mechanism of sorafenib resistance in liver cancer. Nat Med 2014;20:1138-46.
6. Liang Y, Zheng T, Song R, et al. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma. Hepatology 2013;57:1847-57.
7. Vidal SJ, Rodriguez-Bravo V, Galsky M, et al. Targeting cancer stem cells to suppress acquired chemotherapy resistance. Oncogene 2014;33:4451-63.
8. Newell P, Toffanin S, Villanueva A, et al. Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol 2009;51:725-33.
9. Huynh H, Ngo VC, Fargnoli J, et al. Brivanib alaninate, a dual inhibitor of vascular endothelial growth factor receptor and fibroblast growth factor receptor tyrosine kinases, induces growth inhibition in mouse models of human hepatocellular carcinoma. Clin Cancer Res 2008;14:6146-53.
10. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008;133:704-15.
11. Villanueva A, Portela A, Sayols S, et al. DNA Methylation-based prognosis and epidrivers in hepatocellular carcinoma. Hepatology 2015;61:1945-56.
12. Chiang DY, Villanueva A, Hoshida Y, et al. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res 2008;68:6779-88.
13. Villanueva A, Chiang DY, Newell P, et al. Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology 2008;135:1972-83, 1983.e1-11.
14. Villanueva A, Hoshida Y, Battiston C, et al. Combining clinical, pathology, and gene expression data to predict recurrence of hepatocellular carcinoma. Gastroenterology 2011;140:1501-12.e2.
15. Wurmbach E, Chen YB, Khitrov G, et al. Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology 2007;45:938-47.
16. Boyault S, Rickman DS, de Reyniès A, et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets. Hepatology 2007;45:42-52.
17. Tovar V, Alsinet C, Villanueva A, et al. IGF activation in a molecular subclass of hepatocellular carcinoma and pre-clinical efficacy of IGF-1R blockage. J Hepatol 2010;52:550-9.
18. Hoshida Y, Nijman SM, Kobayashi M, et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. Cancer Res 2009;69:7385-92.
19. Yamashita T and Wang XW. Cancer stem cells in the development of liver cancer. J Clin Invest 2013;123:1911-18.
20. Yamashita T, Forgues M, Wang W, et al. EpCAM and alpha-fetoprotein expression defines novel prognostic subtypes of hepatocellular carcinoma. Cancer Res 2008;68:1451-61.
21. Cairo S, Armengol C, De Reyniès A, et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008;14:471-84.
22. Blivet-Van Eggelpoel MJ, Chettouh H, Fartoux L, et al. Epidermal growth factor receptor and HER-3 restrict cell response to sorafenib in hepatocellular carcinoma cells. J Hepatol 2012;57:108-15.
23. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2005;2:e73.
24. Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 2001;293:876-80.
25. Mirzoeva OK, Das D, Heiser LM, et al. Basal subtype and MAPK/ERK kinase (MEK)-phosphoinositide 3-kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69:565-72.
26. Goetz EM, Ghandi M, Treacy DJ, et al. ERK mutations confer resistance to mitogen-activated protein kinase pathway inhibitors. Cancer Res 2014;74:7079-89.
27. Chen KF, Chen HL, Tai WT, et al. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. J Pharmacol Exp Ther 2011;337:155-61.
28. Chow AK, Ng L, Lam CS, et al. The Enhanced metastatic potential of hepatocellular carcinoma (HCC) cells with sorafenib resistance. PLoS ONE 2013;8:e78675.
29. Denduluri SK, Idowu O, Wang Z, et al. Insulin-like growth factor (IGF) signaling in tumorigenesis and the development of cancer drug resistance. Genes Dis 2015;2:13-25.
30. Ezzoukhry Z, Louandre C, Trécherel E, et al. EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib. Int J Cancer 2012;131:2961-9.
31. Sonpavde G, Willey CD, Sudarshan S. Fibroblast growth factor receptors as therapeutic targets in clear-cell renal cell carcinoma. Expert Opin Investig Drugs 2014;23:305-15.
32. Shan J, Shen J, Liu L, et al. Nanog regulates self-renewal of cancer stem cells through the insulin-like growth factor pathway in human hepatocellular carcinoma. Hepatology 2012;56:1004-14.
33. Desbois-Mouthon C, Cacheux W, Blivet-Van Eggelpoël MJ, et al. Impact of IGF-1R/ EGFR cross-talks on hepatoma cell sensitivity to gefitinib. Int J Cancer 2006;119:2557-66.